Payment overview · 2025
General Payments
$404.29
16 reported records · 6 companies
Healthcare provider profile · identity verified
Matthew D Harvison, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TRUMANN, AR · NPI 1003278052
Verified facts
What the public records show
CMS Open Payments records show Matthew D Harvison, MD received $404.29 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $289.80 | 71.7% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.06 | 11.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.00 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.35 | 5.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.08 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.00 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $404.29 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $238.40 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $189.81 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.41 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.06 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
157 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 84 |
| Omeprazole | Omeprazole | 310 | 51 |
| Gabapentin | Gabapentin | 292 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 45 |
| Lisinopril | Lisinopril | 192 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 157 | 35 |
| Furosemide | Furosemide | 155 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 47 |
| Losartan Potassium | Losartan Potassium | 126 | 22 |
| Pregabalin | Pregabalin | 126 | 19 |
| Trazodone Hcl | Trazodone Hcl | 122 | 28 |
| Metformin Hcl | Metformin Hcl | 120 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 21 |
| Potassium Chloride | Potassium Chloride | 112 | 19 |
| Carvedilol | Carvedilol | 106 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 19 |
| Simvastatin | Simvastatin | 94 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 17 |
| Spironolactone | Spironolactone | 89 | 17 |
| Montelukast Sodium | Montelukast Sodium | 83 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 19 |
| Tramadol Hcl | Tramadol Hcl | 81 | 21 |
| Alprazolam | Alprazolam | 78 | 17 |
| Ezetimibe | Ezetimibe | 77 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 17 |
| Sertraline Hcl | Sertraline Hcl | 76 | 16 |
| Famotidine | Famotidine | 75 | 19 |
| Meloxicam | Meloxicam | 74 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 12 |
| Glipizide | Glipizide | 65 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 18 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Baclofen | Baclofen | 58 | 11 |
| Farxiga | Dapagliflozin Propanediol | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 11 |
| Jardiance | Empagliflozin | 54 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 13 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Sucralfate | Sucralfate | 38 | 11 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 14 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 12 |
| Roflumilast | Roflumilast | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Prednisone | Prednisone | 15 | 14 |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 12 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $404.29 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, GVOKE HYPOPEN, NURTEC ODT, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error